---
name: Tirzepatide
aliases:
  - Mounjaro
  - Zepbound
classes:
  - glp-1-receptor-agonists
  - gip-receptor-agonists
targets:
  - glp-1r
  - gipr
evidence_floor: human_rct
index: 20
---

import ClaimCallout from "../../components/ClaimCallout.astro";

## Overview
Tirzepatide is a synthetic peptide designed as a **dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor**.

It has been extensively studied in human randomized controlled trials for metabolic indications, including type 2 diabetes and obesity, and represents a new generation of **multi-receptor incretin-based therapies**.

---

## Mechanism of action
<ClaimCallout
  claim="Dual agonism of the GIP and GLP-1 receptors is associated with improved glycemic control and significant body-weight reduction in humans."
  evidence="human_rct"
  confidence="high"
/>

Tirzepatide activates both:
- **GLP-1 receptors**, involved in glucose-dependent insulin secretion, appetite regulation, and delayed gastric emptying  
- **GIP receptors**, which play a role in postprandial insulin secretion and may modulate adipose and central metabolic pathways  

The combined receptor engagement is hypothesized to produce **additive or synergistic metabolic effects**, although the precise contribution of each receptor to clinical outcomes remains an area of active investigation.

---

## Evidence summary
A large body of **phase 3 human randomized controlled trials** supports the metabolic effects of tirzepatide.

Across major study programs, tirzepatide has been associated with:
- Greater reductions in **HbA1c** compared with several active comparators  
- Substantial **dose-dependent body-weight reductions**  
- Improvements in cardiometabolic risk markers, including blood pressure and lipid parameters  

Head-to-head trials against GLP-1 receptor agonists suggest **numerically greater weight loss** at higher tirzepatide doses, though study populations and designs vary.

---

## Safety & known risks
Across clinical trials, tirzepatide demonstrated a **safety profile broadly consistent with incretin-based therapies**.

Most commonly reported adverse events include:
- Nausea  
- Vomiting  
- Diarrhea  
- Constipation  

These effects were:
- Dose-dependent  
- Most frequent during dose escalation  
- Generally reported as mild to moderate  

Serious adverse events were uncommon in trial populations but continue to be monitored in long-term and post-marketing studies.

---

## ðŸ”¬ Clinical & observational context *(research-oriented)*

> **Important:** This section summarizes information reported in scientific literature and does not constitute medical advice.

### Reported dosing ranges and titration (research context)
In phase 3 trials, tirzepatide was evaluated at **weekly doses of 5 mg, 10 mg, and 15 mg**, following a **gradual titration schedule**.

Typical trial titration involved:
- Initiation at a low weekly dose  
- Stepwise escalation every **4 weeks**  
- Advancement to the assigned maintenance dose over several months  

Lower starting doses were used to improve gastrointestinal tolerability and were not evaluated for primary efficacy.

---

### Observed effects and timelines
Across trials:
- **Glycemic improvements** were observed after escalation beyond initial doses  
- **Weight reduction** progressed throughout titration and continued during maintenance  
- Maximal weight outcomes were assessed after **long-term exposure at maintenance dose**

Most phase 3 studies followed participants for **40â€“72 weeks**, allowing assessment of both magnitude and durability of effects.

---

### Reported metabolic outcomes
In obesity-focused trials, tirzepatide was associated with:
- **Mean body-weight reductions** exceeding **15%** at higher doses  
- A high proportion of participants achieving **â‰¥10% and â‰¥20% weight loss**  
- Reductions in **waist circumference** and improvements in **glycemic markers**, even in participants without diabetes  

In diabetes-focused trials:
- **HbA1c reductions** of approximately **2 percentage points** were reported  
- Concomitant weight loss and improvements in cardiometabolic markers were observed  

---

### Mitigation strategies discussed in trials
Clinical publications describe:
- Gradual titration as the primary strategy for tolerability  
- Temporary dose holds or delays during gastrointestinal intolerance  
- Stabilization of adverse events during maintenance phases  

These approaches were **protocol-defined trial strategies**, not individualized recommendations.

---

### Studied or hypothesised interactions
In research settings, tirzepatide has been:
- Compared directly with GLP-1 receptor agonists  
- Evaluated alongside lifestyle interventions  
- Discussed as a reference point for newer multi-receptor agonists  

The relative contribution of GIP receptor agonism to observed outcomes remains an area of ongoing research.

---

## Unknowns & research gaps
Despite extensive clinical evaluation, several questions remain:
- Long-term outcomes following treatment discontinuation  
- Mechanistic separation of GLP-1 vs GIP effects  
- Inter-individual variability in response  
- Long-term safety beyond current follow-up durations  

Ongoing trials and real-world evidence are expected to further clarify these areas.

---

## References
- Frias JP et al. *Efficacy and safety of tirzepatide in type 2 diabetes.*  
  **New England Journal of Medicine**, 2021. PMID: **34170647**

- Jastreboff AM et al. *Tirzepatide once weekly for the treatment of obesity.*  
  **New England Journal of Medicine**, 2022. PMID: **35658024**

- Rosenstock J et al. *Once-weekly tirzepatide versus semaglutide.*  
  **NEJM**, 2021. PMID: **34170648**
